Schedule of notes payable |
Notes payable consisted of the following at June 30, 2022 and December 31, 2021 (in thousands except for number of underlying shares) excluding the revolving line of credit agreement with related party discussed below:
Year
Issued
|
|
Interest Rate
Range
|
|
|
Term of Notes
|
|
Conversion
Price
|
|
|
Principal
Outstanding June 30, 2022
|
|
|
Unamortized Discount June 30, 2022
|
|
|
Carrying
Amount June 30, 2022
|
|
|
Underlying Shares June 30, 2022
|
|
|
Notes payable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2013
|
|
10%
|
|
|
Due on demand
|
|
|
—
|
|
|
$
|
734
|
|
|
$
|
—
|
|
|
$
|
734
|
|
|
|
—
|
|
|
2021
|
|
11%
|
|
|
Due on demand - 2 years
|
|
|
—
|
|
|
|
2,793
|
|
|
|
—
|
|
|
|
2,793
|
|
|
|
—
|
|
|
2022
|
|
11%-41%
|
|
|
Due on demand - 10 month
|
|
|
—
|
|
|
|
2,985
|
|
|
|
118
|
|
|
|
2,867
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
6,512
|
|
|
$
|
118
|
|
|
$
|
6,394
|
|
|
|
—
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
$
|
6,512
|
|
|
$
|
118
|
|
|
$
|
6,394
|
|
|
|
—
|
|
|
Notes payable - related parties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
12%
|
|
|
Due on demand
|
|
|
—
|
|
|
|
100
|
|
|
|
—
|
|
|
|
100
|
|
|
|
—
|
|
|
2021
|
|
12%
|
|
|
Due on demand
|
|
|
—
|
|
|
|
700
|
|
|
|
—
|
|
|
|
700
|
|
|
|
—
|
|
|
2022
|
|
10%-12%
|
|
|
Due on demand
|
|
|
—
|
|
|
|
2,071
|
|
|
|
—
|
|
|
|
2,071
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,871
|
|
|
$
|
—
|
|
|
$
|
2,871
|
|
|
|
—
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
$
|
2,871
|
|
|
$
|
—
|
|
|
$
|
2,871
|
|
|
|
—
|
|
|
Convertible notes payable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
12%
|
|
|
3 years
|
|
$
|
10.00
|
|
(b)
|
|
3,150
|
|
|
|
—
|
|
|
|
3,150
|
|
|
|
323,016
|
|
|
2021
|
|
2%
|
|
|
3 years
|
|
$
|
0.37
|
|
(a)
|
|
14,490
|
|
|
|
3,578
|
|
|
|
10,912
|
|
|
|
40,739,519
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
17,640
|
|
|
$
|
3,578
|
|
|
$
|
14,062
|
|
|
|
41,062,535
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
$
|
17,640
|
|
|
$
|
3,578
|
|
|
$
|
14,062
|
|
|
|
41,062,535
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
$
|
27,023
|
|
|
$
|
3,696
|
|
|
$
|
23,326
|
|
|
|
41,062,535
|
|
|
Year
Issued
|
|
Interest Rate
Range
|
|
|
Term of Notes
|
|
Conversion
Price
|
|
|
Principal
Outstanding
December 31,
2021
|
|
|
Unamortized
Discount
December 31,
2021
|
|
|
Carrying
Amount
December 31,
2021
|
|
|
Underlying Shares
December 31, 2021
|
|
|
Notes payable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2013
|
|
10%
|
|
|
Due on demand
|
|
|
—
|
|
|
$
|
869
|
|
|
$
|
—
|
|
|
$
|
869
|
|
|
|
—
|
|
|
2021
|
|
11%
|
|
|
Due on demand - 2 years
|
|
|
—
|
|
|
|
3,030
|
|
|
|
—
|
|
|
|
3,030
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,899
|
|
|
$
|
—
|
|
|
$
|
3,899
|
|
|
|
—
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
$
|
2,399
|
|
|
$
|
—
|
|
|
$
|
2,399
|
|
|
|
—
|
|
|
|
|
|
|
|
|
Non-current
|
|
|
|
|
|
$
|
1,500
|
|
|
$
|
—
|
|
|
$
|
1,500
|
|
|
|
—
|
|
|
Notes payable - related parties
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
12%
|
|
|
Due on demand
|
|
|
—
|
|
|
$
|
100
|
|
|
$
|
—
|
|
|
$
|
100
|
|
|
|
—
|
|
|
2021
|
|
12%
|
|
|
Due on demand
|
|
|
—
|
|
|
|
700
|
|
|
|
—
|
|
|
|
700
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
800
|
|
|
$
|
—
|
|
|
$
|
800
|
|
|
|
—
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
$
|
800
|
|
|
$
|
—
|
|
|
$
|
800
|
|
|
|
—
|
|
|
Convertible notes payable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
12%
|
|
|
3 years
|
|
$
|
10.00
|
|
(b)
|
|
3,150
|
|
|
|
—
|
|
|
|
3,150
|
|
|
|
316,756
|
|
|
2021
|
|
2%
|
|
|
3 years
|
|
$
|
1.48
|
|
(a)
|
|
14,490
|
|
|
|
4,332
|
|
|
|
10,158
|
|
|
|
9,856,343
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
17,640
|
|
|
$
|
4,332
|
|
|
$
|
13,308
|
|
|
|
10,173,099
|
|
|
|
|
|
|
|
|
Current
|
|
|
|
|
|
$
|
14,490
|
|
|
$
|
4,332
|
|
|
$
|
10,158
|
|
|
|
9,856,343
|
|
|
|
|
|
|
|
|
Non-current
|
|
|
|
|
|
$
|
3,150
|
|
|
$
|
—
|
|
|
$
|
3,150
|
|
|
|
316,756
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
$
|
22,339
|
|
|
$
|
4,332
|
|
|
$
|
18,007
|
|
|
$
|
10,173,099
|
|
|
|
(a)
|
The notes are convertible into Emmaus Life Sciences, Inc. shares. Beginning February 28, 2022, the note holders became entitled to call for early redemption of the convertible notes payable, because the Company common stock was not approved for listing on a Trading Market (as defined in the agreement). Accordingly, the notes are classified as current liabilities.
|
|
(b)
|
This note is convertible into shares of EMI Holding, Inc., a wholly owned subsidiary of Emmaus Life Sciences, Inc.
|
|